Mesenchymal Stromal Cells: Heterogeneity and Therapeutical Applications
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Mesenchymal stromal cells nowadays emerge as a major player in the field of regenerative medicine and translational research. They constitute, with their derived products, the most frequently used cell type in different therapies. However, their heterogeneity, including different subpopulations, the anatomic source of isolation, and high donor-to-donor variability, constitutes a major controversial issue that affects their use in clinical applications. Furthermore, the intrinsic and extrinsic molecular mechanisms underlying their self-renewal and fate specification are still not completely elucidated. This review dissects the different heterogeneity aspects of the tissue source associated with a distinct developmental origin that need to be considered when generating homogenous products before their usage for clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370 · cited 4×
“MSCs isolated from cord blood have been shown to have a unique chondrogenic differentiation potential in vivo and reveal higher replicative rates compared to BM-MSCs [51,57,109].”
BackgroundInfluentialSecretion of angiogenic and antiapoptotic factors by human adipose stromal cells
Rehman, J., Traktuev, D., Li, J., Merfeld-Clauss, S., Temm-Grove, C. J., Bovenkerk, J. E., Pell, C. L., Johnstone, B. H., Considine, R. V., & March, K. L. (2004) · Circulation · doi:10.1161/01.cir.0000121425.42966.f1 · Cited by 2,269 · cited 1×
“However, AT-MSCs have also been shown to secrete several factors that support tissue regeneration, such as vascular endothelial cell growth factor (VEGF) and HGF, thus having beneficial effects that can be used for cell-based cardiovascular gene therapy of ischemic tissue [71].”
BackgroundGnecchi, M., He, H., Liang, O. D., Melo, L. G., Morello, F., Mu, H., Noiseux, N., Zhang, L., Pratt, R. E., Ingwall, J. S., et al. (2005) · Nature Medicine · doi:10.1038/nm0405-367 · Cited by 1,677 · cited 1×
“Moreover, the immunomodulatory effects of BM-MSCs were used for treatment of patients suffering from ischemic injury in numerous clinical trials and have been proved to be beneficiary [61].”
BackgroundChoudhery, M. S., Badowski, M., Muise, A., Pierce, J., & Harris, D. T. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-8 · Cited by 529 · cited 9×
“Adipose Tissue-Derived MSCs (AT-MSCs) Adipose tissue is another alternative, less invasive source for the isolation of higher initial yields of MSCs than from the bone marrow, with higher proliferative capacity in vitro [57].”
BackgroundInfluentialHEO, J. S., CHOI, Y., KIM, H.-S., & KIM, H. O. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2413 · Cited by 495
Siegel, G., Kluba, T., Hermanutz-Klein, U., Bieback, K., Northoff, H., & Schäfer, R. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-146 · Cited by 493
Sacchetti, B., Funari, A., Remoli, C., Giannicola, G., Kogler, G., Liedtke, S., Cossu, G., Serafini, M., Sampaolesi, M., Tagliafico, E., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.05.011 · Cited by 428
Li, C.-Y., Wu, X.-Y., Tong, J.-B., Yang, X.-X., Zhao, J.-L., Zheng, Q.-F., Zhao, G.-B., & Ma, Z.-J. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0066-5 · Cited by 410 · cited 3×
“In comparison to BM-MSCs, AT-MSCs exhibit lower chondrogenic and osteogenic potentials [59,79].”
BackgroundNoël, D., Caton, D., Roche, S., Bony, C., Lehmann, S., Casteilla, L., Jorgensen, C., & Cousin, B. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.12.022 · Cited by 343
LI, X., BAI, J., JI, X., LI, R., XUAN, Y., & WANG, Y. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1821 · Cited by 301
Zaim, M., Karaman, S., Cetin, G., & Isik, S. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1438-x · Cited by 294 · cited 1×
“Other groups reported a decreased adipogenic and osteogenic potential of BM-MSCs with increasing donor age, with no changes in the chondrogenic differentiation potential [31,32].”
BackgroundWu, M., Zhang, R., Zou, Q., Chen, Y., Zhou, M., Li, X., Ran, R., & Chen, Q. (2018) · Scientific Reports · doi:10.1038/s41598-018-23396-1 · Cited by 206
Karagianni, M., Brinkmann, I., Kinzebach, S., Grassl, M., Weiss, C., Bugert, P., & Bieback, K. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2012.11.001 · Cited by 43
Cited by
Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration
Ghoneim, M. A., Gabr, M. M., El-Halawani, S. M., & Refaie, A. F. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03636-0 · Cited by 49
The potency of mesenchymal stem/stromal cells: does donor sex matter?
Maged, G., Abdelsamed, M. A., Wang, H., & Lotfy, A. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03722-3 · Cited by 42
“1 Factors that can contribute to MSCs heterogeneity rate, immunomodulatory properties, and gene expression profiles [16, 19].”
BackgroundKannan, S., Gokul Krishna, S., Gupta, P. K., & Kolkundkar, U. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-62544-8 · Cited by 39
Metadata
- Authors
- Ouzin, M., & Kogler, G.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-08-10
- Volume
- 12
- Issue
- 16
- Pages
- 2039
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W4385737544
- Cited by
- 42
- References
- 13
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.